Table of Contents

Ishrat Husain and Chase Thompson: 1. Historical Overview
Laurie Highbed and Ben Sessa: 2. The psychotherapeutic component of psychedelic medicine (includes set, setting, anticipation, expectancy, preparation, integration)
David Erritzoe and James Rucker: 3. Psilocybin
Michael Mithoefer and David Presti: 4. MDMA
Mihai Avram, Felix Müller and Stefan Borgwardt: 5. Lysergic Acid Diethylamid: In Search of the Wonder Drug
Daniel Perkins, Simon Ruffell, and Jerome Sarris: 6. Ayahuasca
Deborah Mash: 7. Ibogaine
James Linden and Daniel Robin: 8. Other psychedelics
Joshua Di Vincenzo, Joshua Rosenblat and Roger McIntyre: 9. Ketamine
Jo Neil, Mohammed Shahid, Rosalind Gittins, Anne K Schalg and Frank I Tarazi: 10. Risks and side effects associated with the use of psychedelics
David Castle, David Nutt and Nicole Ledwos: 11. Psychedelics as psychiatric medicines: current challenges and future prospects

About the Author

David Nutt is a psychiatrist and the Edmond J. Safra Professor of Neuropsychopharmacology in Imperial College London. He is currently Founding Chair of the charity DrugScience.org.uk and has been president of the European Brain Council, the BAP, BNA, and ECNP. David has published 35 books and over 1000 research papers that define his many landmark contributions to psychopharmacology including GABA and noradrenaline receptor function in anxiety disorders, serotonin
function in depression, endorphin and dopamine function in addiction and the neuroscience and clinical utility of psychedelics. Some of this has been made into films e.g.
on Netflix and on the BBC and a play . He broadcasts widely to the general public on pharmacology and psychiatric matters, has over 60k followers on twitter and has his own very popular podcast... David Castle is Inaugural Scientific Director of the Centre for Complex Interventions (CCI) at the Centre for
Addictions and Mental Health (CAMH), Toronto, Canada; and Professor, Department of Psychiatry, The University of Toronto. He has wide clinical and research interests, encompassing schizophrenia and related disorders, bipolar disorder, OCD
spectrum disorders and disorders of body image. He has a longstanding interest in the impact of licit and illicit substances on the brain and body, and is actively engaged in a series of trials investigating psychedelics as psychiatric medicines. He has published widely and is a frequent speaker at scientific meetings.